Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Iyengar N, Morris P, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 167-167. DOI: 10.1200/jco.2013.31.26_suppl.167.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureDistant disease-free survivalEarly breast cancerBreast cancerHER2-positive early breast cancerMedian left ventricular ejection fractionLong-term cardiac safetyRandomized phase III studyEarly-stage breast cancerLong-term cardiac toxicityTrial BTrial AAnthracycline-based regimensDose-dense doxorubicinPre-existing hypertensionPhase II studyDisease-free survivalPhase III studyVentricular ejection fractionStage breast cancerDd ACMonths 44II studyIII studyLong‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 2013, 119: 3943-3951. PMID: 24037735, DOI: 10.1002/cncr.28284.Peer-Reviewed Original ResearchConceptsDistant disease-free survivalCongestive heart failureEarly breast cancerHuman epidermal growth factor receptor 2Breast cancerTrial ALong-term cardiac safetyEpidermal growth factor receptor 2Dose-dense doxorubicinDose-dense chemotherapyAnti-HER2 therapyDisease-free survivalPhase 2 trialGrowth factor receptor 2Long-term incidenceFactor receptor 2Previous hypertensionCumulative incidenceHeart failureAdditional patientsCardiac safetyLower riskReceptor 2PatientsTrial B.Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Morris P, Iyengar N, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 630-630. DOI: 10.1200/jco.2013.31.15_suppl.630.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureDistant disease-free survivalEarly breast cancerBreast cancerHER2-positive early breast cancerMedian left ventricular ejection fractionLong-term cardiac safetyMedian f/uRandomized phase III studyEarly-stage breast cancerLong-term cardiac toxicityTrial BTrial AAnthracycline-based regimensCompletion of ACDose-dense doxorubicinPre-existing hypertensionDisease-free survivalPhase II studyPhase III studyVentricular ejection fractionStage breast cancerDd ACMonths 44